Traceability for cancer therapy

The secondary standard ionisation chambers at NPL that were used in the establishment of traceable 177Lu measurements at hospitals.

Scientists from the National Physical Laboratory (NPL) have worked to establish traceability for a molecular radiotherapy treatment for patients suffering from neuroendocrine tumours.

Neuroendocrine tumours are usually found in the or lungs and arise from hormone-producing cells. A new treatment involves the administration of a peptide, radiolabelled with the beta- and gamma-emitting radionuclide Lutetium-177 (177Lu), which irradiates the widespread without causing excessive damage to surrounding healthy tissue. The treatment can also be followed by , taking advantage of the gamma-emission of the radionuclide.

Following a series of clinical trials, this radiopharmaceutical is now beginning to be used routinely for molecular radionuclide therapy (MRT) throughout the UK and Europe.

A team of NPL scientists first established a link to the International Reference System by standardising 177Lu as part of an international comparison in 2011. Once that had been established, NPL invited UK and European hospitals that regularly use this radionuclide to participate in a blind exercise to measure the radioactivity in samples of 177Lu. From the results of this exercise, the hospitals could demonstrate traceability, ensuring regulatory compliance and . The results showed that the majority of participants have the capability to measure the 177Lu activity to within 2%, with only three participants showing variations higher than this.

The same team of scientists is now working on the next important step towards establishing traceability for 177Lu imaging, within the framework of a European Metrology Research Programme (EMRP) project called 'Metrology for Molecular Radiotherapy'.

Related Stories

Benefits of radionuclide therapy for neuroendocrine tumors

date Sep 20, 2011

According to new Dutch research featured in the September issue of The Journal of Nuclear Medicine, a peptide receptor radiolabeled therapy (PRRT), [177Lu-DOTA0,Tyr3]Octreotate (177Lu-octreotate) , is effective not only i ...

New radioisotope will improve cancer therapy

date Apr 22, 2011

The high neutron flux at the Institut Laue-Langevin (ILL) has produced samples of 161Tb, an isotope of terbium with better properties for cancer therapy than existing radiopharmaceutical treatments. Researcher ...

NPL unveils new equipment to make cancer treatment safer

date Nov 14, 2008

A new piece of medical technology unveiled at the National Physical Laboratory (NPL) today will help improve the success rates of radiotherapy cancer treatments. The new clinical electron linear accelerator (linac) will help ...

High-impact radiopeptide therapy halts neuroendocrine cancer

date Jun 06, 2011

Research introduced at SNM's 58th Annual Meeting could be a sign of hope for patients with neuroendocrine cancer not responding well to standard therapies. Most radiotherapies use medical isotopes that emit beta radiation. ...

Recommended for you

Using healthy skin to identify cancer's origins

date 17 hours ago

Normal skin contains an unexpectedly high number of cancer-associated mutations, according to a study published in Science. The findings illuminate the first steps cells take towards becoming a cancer and de ...

Gender differences in receipt of end-of-life care

date 18 hours ago

(HealthDay)—There are gender differences in receipt of end-of-life (EoL) care among terminally ill cancer patients, with male patients more likely to receive intensive care unit (ICU) care, according to ...

Scientists unveil prostate cancer's 'Rosetta Stone'

date 19 hours ago

Almost 90 per cent of men with advanced prostate cancer carry genetic mutations in their tumours that could be targeted by either existing or new cancer drugs, a landmark new study reveals.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.